Dicot AB (publ) has investigated an alternative technology for future large-scale production of starting material for the company's drug candidate. The results show that the new technique involving plant cell cultures works on a laboratory scale. In 2022 Dicot started a research project with Uppsala University and the W. Szafer Institute of Botany to investigate whether the starting material of the drug substance in LIB-01 can be produced by using plant cell cultures; an established technology for large scale commercial production of several drug substances from nature.

The company notifies that the project has been successful in demonstrating that the technology works on a laboratory scale. Dicot will now proceed with the technology and carry out scale-up tests and optimization work to evaluate the technology on a larger scale and make comparisons with the existing process - where the starting material is extracted from natural plant material - that will continue simultaneously.